Login to Your Account



FDA Tweaks PDUFA for Biosimilar User Fees

By Mari Serebrov


Tuesday, May 10, 2011
WASHINGTON – The FDA sees a $150,000 annual biosimilar product development fee as the solution to a unique challenge posed by the new 351(k) approval path.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription